Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 30, Issue 10, Pages 756-766Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2019.07.014
Keywords
-
Categories
Funding
- Ministerio de Ciencia, Innovacion y Universidades - Fondo Europeo de Desarrollo Regional (FEDER) [SAF2016-80286-R]
Ask authors/readers for more resources
Musculoskeletal disorders represent an elevated socioeconomic burden for developed aging societies. Osteoporosis (OP) has been treated with antiresorptive therapies or with teriparatide that was until recently the only anabolic therapy. However, approval of osteoporosis treatment in postmenopausal women with abaloparatide, which is an analog of parathyroid hormone related peptide (PTHrP), has created a new alternative for OP management. The success of this new treatment is related to differential mechanisms of activation of PTH receptor type 1 (PTH1R) by abaloparatide and PTH. Here, we address the distinguishing mechanisms of PTH11 activation; the effects of PTH1R stimulation in osteoblast, osteocytes, and chondrocytes; the dif ferences between PTH and abaloparatide actions on PTH1R; potential safety concerns; and future perspectives about abaloparatide use in other musculoskeletal disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available